What is Earli?
Earli Inc. is dedicated to transforming cancer into a benign experience by identifying and eradicating it in its nascent stages. The company's proprietary technology centers on programmable genetic constructs designed to activate exclusively within cancer cells, prompting them to self-reveal and subsequently self-destruct. This innovative therapeutic strategy positions Earli at the forefront of precision oncology, aiming to significantly improve patient outcomes through early intervention.
How much funding has Earli raised?
Earli has raised a total of $100M across 2 funding rounds:
Series A
$40M
Unspecified
$60M
Series A (2021): $40M with participation from Casdin Capital , LLC, Khosla Ventures, Sands Capital Management, Andreessen Horowitz, and Perceptive Advisors LLC
Unspecified (2024): $60M, investors not publicly disclosed
Key Investors in Earli
Khosla Ventures
Khosla Ventures is a venture capital firm known for investing in disruptive technologies across various sectors, including healthcare and biotechnology.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm that invests in groundbreaking technology companies, often focusing on transformative innovations.
Sands Capital Management
Sands Capital Management is an investment firm that typically backs companies with strong growth potential, often in the technology and healthcare sectors.
What's next for Earli?
The recent major strategic investment signals a pivotal moment for Earli, likely enabling the company to accelerate its research and development pipelines, expand its clinical trial operations, and scale its unique therapeutic platform. This infusion of capital is expected to propel Earli towards achieving its mission of making cancer a manageable condition, potentially marking a new era in oncological treatment paradigms.
See full Earli company page
